PCM
BLUE

Prelude Capital Management’s bluebird bio BLUE Stock Holding History

Prelude Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-193
Closed -$318K – 1715
2019
Q2 		$318K Buy
+193
New +$334K 0.02% 595
2015
Q1 		– Sell
-77
Closed -$92K – 1940
2014
Q4 		$92K Buy
+77
New +$51.5K 0.01% 1034

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's BLUE Position: Q2 2023 in Review

Prelude Capital Management sold out of bluebird bio (BLUE) in Q2 2023, closing a stake of 1,333 shares — an estimated $84.8K sold.

Prelude Capital Management first reported a position in BLUE in Q1 2015 and held it in 12 quarters. The position peaked at $586K in Q2 2020. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.

  • Prelude Capital Management reported no remaining bluebird bio position as of Q2 2023 after selling out during the quarter.
  • Prelude Capital Management sold 1,333 bluebird bio shares in Q2 2023, an estimated $84.8K.
  • Prelude Capital Management first reported a position in bluebird bio in Q1 2015 and held it in 12 quarters.
  • Prelude Capital Management's bluebird bio position peaked at $586K in Q2 2020.
  • 175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.

Based on Prelude Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.